• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    10/13/23 1:31:10 PM ET
    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATPC alert in real time by email

    Gainers

    • Bio-Path Hldgs (NASDAQ:BPTH) shares rose 60.6% to $0.63 during Friday's regular session. Bio-Path Hldgs's stock is trading at a volume of 111.1 million shares as of 13:30 EST. This is 15820.7% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million.
    • Processa Pharma (NASDAQ:PCSA) stock moved upwards by 22.69% to $0.41. The current volume of 5.1 million shares is 2367.4% of Processa Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $9.9 million.
    • Harpoon Therapeutics (NASDAQ:HARP) stock increased by 20.66% to $3.97. As of 13:30 EST, Harpoon Therapeutics's stock is trading at a volume of 80.5K, which is 212.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.9 million.
    • SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 20.0% to $1.29. The current volume of 1.0 million shares is 417.6% of SELLAS Life Sciences Gr's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $36.5 million.
    • Agape ATP (NASDAQ:ATPC) stock increased by 19.99% to $1.32. As of 13:30 EST, this security is trading at a volume of 2.5 million shares, making up 161.0% of its average full-day volume over the last 100 days. The company's market cap stands at $99.5 million.
    • Assure Hldgs (NASDAQ:IONM) shares rose 19.56% to $0.33. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 123.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.2 million.

    Losers

    • Bellerophon Therapeutics (NASDAQ:BLPH) stock decreased by 64.9% to $0.14 during Friday's regular session. Trading volume for this security as of 13:30 EST is 3.3 million, which is 2157.8% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million.
    • Outset Medical (NASDAQ:OM) shares declined by 50.23% to $3.37. Trading volume for Outset Medical's stock is 6.2 million as of 13:30 EST. This is 956.8% of its average full-day volume over the last 100 days. The company's market cap stands at $167.7 million.
    • Harmony Biosciences (NASDAQ:HRMY) stock declined by 31.43% to $20.75. Harmony Biosciences's stock is trading at a volume of 5.0 million shares as of 13:30 EST. This is 885.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 billion.
    • Comera Life Sciences (NASDAQ:CMRA) stock decreased by 21.16% to $0.25. Trading volume for this security as of 13:30 EST is 357.6K, which is 365.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.7 million.
    • Catalyst Biosciences (NASDAQ:CBIO) shares fell 19.76% to $0.33. Catalyst Biosciences's stock is trading at a volume of 762.9K shares as of 13:30 EST. This is 202.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.4 million.
    • PMV Pharma (NASDAQ:PMVP) shares fell 18.88% to $2.02. As of 13:30 EST, this security is trading at a volume of 3.3 million shares, making up 711.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $97.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC
    $BLPH
    $BPTH
    $CBIO

    CompanyDatePrice TargetRatingAnalyst
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Deutsche Bank
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Truist
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/11/2026$46.00Neutral
    UBS
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    Harmony Biosciences Holdings Inc.
    $HRMY
    7/21/2025$48.00Buy
    Truist
    More analyst ratings

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    SEC Filings

    View All

    SEC Form 10-K filed by Processa Pharmaceuticals Inc.

    10-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    3/18/26 4:05:57 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Crescent Biopharma Inc.

    424B3 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    3/17/26 4:00:35 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agape ATP Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Agape ATP Corp (0001713210) (Filer)

    3/12/26 9:00:25 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r

    3/17/26 4:30:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

    - Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leuk

    3/12/26 8:35:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 5, 2026 and were material to each employee's acceptanc

    3/6/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Carulli Michael

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    3/9/26 4:41:27 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by General Counsel & COO Ticktin Robert

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    3/9/26 4:39:59 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Development Officer Jalota Deepika

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    3/9/26 4:36:57 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Harmony Biosciences downgraded by Deutsche Bank

    Deutsche Bank downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:47 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences downgraded by Truist

    Truist downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:36 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Harmony Biosciences with a new price target

    UBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00

    2/11/26 7:39:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

    Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). "We are thrilled to welcome Ja

    7/8/25 7:30:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

    WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear

    2/24/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Har

    2/10/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATPC
    $BLPH
    $BPTH
    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    11/14/24 12:24:48 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/13/24 11:15:11 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care